109 results about "Amino acid change" patented technology

Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.

The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (PCSK9) with greater affinity at neutral pH than at acidic pH. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit pH-dependent binding properties. For example, the present invention includes anti-PCSK9 antibodies which possess one or more histidine substitutions in one or more complementarity determining regions. The antibodies of the invention, with pH-dependent binding properties, remain in circulation and exhibit cholesterol lowering activity for prolonged periods of time in animal subjects as compared to anti-PCSK9 antibodies that do not exhibit pH-dependent binding properties. The antibodies of the invention are therefore useful for treating diseases and disorders related to elevated HDL cholesterol, wherein the antibodies of the invention can be administered to a patient at a lower dose and/or with less frequent dosing as compared to antibodies that do not exhibit pH-dependent binding properties.

The invention discloses application for using an LbCpf1 - RR mutant in a CRISPR/Cpf1 system in plant gene editing. The application for using the LbCpf1 - RR mutant in the CRISPR/Cpf1 system in plant gene editing uses an OsPDS gene and an OsSBEIIb gene as target genes, constructs a target double loci of one gene and a series of vectors of two genes, and utilizes an agrobacterium-mediated transformation method to import the vectors into rice callus, and rice plants with the target gene knockout are successfully obtained by using the LbCpf1-RR mutant. The only difference between the LbCpf1-RR mutant and the protein LbCpf1 is that the 532nd amino acid changes from G to R, and the 595th amino acid changes from K to R. The LbCpf1-RR mutant provided by the application for using the LbCpf1 - RR mutant in the CRISPR/Cpf1 system in plant gene editing expands the PAM site sequence identified by the LbCpf1-RR mutant, so that the editing range of the CRISPR/Cpf1 system in rice genome is expanded, great significance for promoting the application of the system in the field of plant genome editing is achieved. The application for using the LbCpf1 - RR mutant in the CRISPR/Cpf1 system in plant geneediting has great application value.

Provided are synthetic peptides based on a native sequence of HIV gp41 HR2 except that the synthetic peptides have a plurality of amino acid replacements comprising (a) a helix-promoting amino acid, or (b) a combination of helix-promoting amino acids, and charged amino acids introduced to form ion pairs in the synthetic peptide; wherein the synthetic peptides demonstrate an unexpected, improved biological activity, as compared to a peptide having an amino acid sequence without the plurality of amino acid substitutions. Also provided are polynucleotides encoding synthetic peptide, and methods of using these synthetic peptides in inhibition of, or as compositions to inhibit, transmission of HIV to a target cell.

This invention provides a genetically modified marine luciferase such as Gaussia luciferase, which has high bioluminescence intensity, and has high bioluminescence stability and/or red-shifted wavelength. Specifically disclosed is a luciferase variant with improved optical property obtained by replacing at least one amino acid residue among the amino acid sequence of a marine luciferase at positions corresponding to positions 89 to 118 in the amino acid sequence of Gaussia luciferase (GLuc), wherein an amino acid residue at a position corresponding to at least one selected from positions 89, 90, 95, 97, 100, 108, 112, 115, and 118 in the amino acid sequence of GLuc is replaced by way of conservative amino acid replacement. The above-mentioned replacement in a marine luciferase improves enzymatic activity of the luciferase. Also disclosed is a bioluminescent probe having an improved optical property, which is produced using the luciferase variant of the present invention.

The invention relates to a modified PIN4 gene, the wild type of which is as identified in SEQ ID No. 1, encoding the protein of SEQ ID No. 5, or the wild type of which encodes a protein that has a sequence similarity of at least 80% to SEQ ID No. 5, which modified PIN4 gene encodes a protein that comprises an amino acid change as a result of the modification, and which modified protein is capable of inducing parthenocarpic fruit set when present in a plant. The invention also relates to plants and fruits that carry the gene. Such plants are capable of parthenocarpic fruit set and the fruits do not contain seeds. The invention further relates to use of the gene in breeding and producing plants capable of parthenocarpic fruit set.

The invention provides a novel high-affinity completely humanized antibody which can specifically bind with CD26 as well as a preparation method and application thereof and belongs to the technical field of genetic engineering antibodies. The CD26 is a ubiquitous multifunctional II type transmembrane glycoprotein, has various biological functions and can be interacted with various proteins such as ADA, CD45, FAP-alpha and the like. The invention provides the humanized antibody or a fragment thereof, wherein the antibody or the fragment thereof is capable of specifically binding with the human CD26, preferably the CD26 extracellular domain; the amino acid sequence of the antibody or the fragment thereof comprises an amino acid sequence containing a monoclonal antibody or a fragment thereof or a conjugate of the fragment in any one of 6 complementary determining regions in one of SED ID NO: 2, SED ID NO: 3, SED ID NO: 4, SED ID NO: 6, SED ID NO: 7, and SED ID NO: 8, or an amino acid sequence obtained through amino acid replacement or modification. The obtained anti-CD26 single-chain antibody provided by the invention can highly specifically bind with the CD26 and is simultaneously capable of obviously inhibiting the proliferation, the invasion and the metastasis of tumor cells.

The invention provides a novel full-humanized antibody which is high in affinity and can be specifically combined with CD26, and a preparation method and application thereof, and belongs to the technical field of a genetically engineered antibody. CD26 is a ubiquitous multifunctional II-type transmembrane glycoprotein, has a plurality of biological functions, and can interact with a plurality of proteins, such as ADA, CD45, FAP-alpha and the like. The invention provides an antibody from a human source or a segment thereof. The antibody or the segment thereof is specifically combined with human CD26, and preferably specifically combined with a CD26 extracellular region; an amino acid sequence of the antibody or the segment thereof comprises a monoclonal antibody which is selected from any region of six complementary determining regions containing a group of sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8, or a segment thereof or a conjugate of the segment thereof, or an amino acid sequence which is obtained by amino acid replacement or modification. The anti-CD26 single-chain antibody obtained by the method is highly specifically combined with the CD26, and meanwhile, multiplication of tumor cells can also be obviously inhibited.

The invention discloses a MHC completion database, and an establishment method and application thereof. The MHC completion database comprises a genotype dataset, a HLA typing type dataset, an amino acid changing information dataset, and a HLA haplotype dataset combined together. In the establishment process of the database, LD and HWE are used for the first time for filtering a variation result, and data accuracy is improved. A simple method which is easy to operate is used to obtain SNP distinguishing datasets in least number, and MHC haplotype information is obtained through phasing analysis. Compared with using the whole SNP dataset to perform phasing, the establishment method saves more time, and reduces CPU and memory use, and obtained haplotype information is more accurate. The MHC completion database comprises various datasets in a MHC region, and can effectively complete sites, and lays foundation for deep research of the MHC region.

The invention provides a DNA polymerase with DNA or RNA as a template. The DNA polymerase is obtained through amino acid replacement, including G198W, V222I, E306K, Q354E, A381E and E582K, of klenow fragments of escherichia coli polymerases I. The invention also provides a primer with a stem loop structure and used for constant-temperature nucleic acid amplification. The invention further providesa nucleic acid test technique and a test kit both based on combination between rapid constant-temperature nucleic acid amplification and a Cas test system. The DNA polymerase, the nucleic acid test technique and the test kit can be used for testing nucleic acid targets in test samples at a constant temperature, have the advantages of low cost, short test time, simplicity and convenience in operation, high specificity, high sensitivity and the like, and are particularly applied to POCT (point-of-care testing).

A computer-implemented method and a computer system for identifying a phylogenetic tree from a plurality of biological sequences is provided. Each biological sequence is associated with a sampling date. First, the plurality of biological sequences is aligned and a distance matrix is obtained. Then, a subset of these sequences without any duplicated sequences is selected and a directed graph representation of the subset of biological sequences is generated based the associated sampling dates. Then, a minimum spanning tree is computed from the weighted directed graph representation. Then, in an iterative procedure, the sequences of unsampled evolutionary intermediates are inferred from mutation patterns that reflect the difference in sequence between the nodes in the minimum spanning tree. The new sequences are added with associated time stamps to the sequence set. Then, sets of identical sequences are removed. Then, an optimum branching is recomputed. This step is repeated until no new intermediates are found. In the final step, the sequences that have been set aside in the initializing step are added to the plurality of sequences derived in the update step. From this plurality of sequences an optimum branching is computed and identified as the phylogenetic tree. Amino acid changes repeatedly occurring on the internal branches of the obtained tree can be used to identify sequences and associated viral isolates suitable as vaccine strains for the following influenza season.

The invention discloses a pathogenic mutation of osteogenesis imperfecta and a detection reagent of the pathogenic mutation. According to a novel mutant COL1A1 gene, the mutated COL1A1 gene is a single point mutation c.1822G>A (chr17:48270211), a heterozygous mutation is pathogenic and in a mode of dominant heredity, the amino acid change is p.Gly608Ser, dyssynthesis of I-type collagen in connective tissue is caused by locus mutation of the p.Gly608Ser, and a lesion is formed. A kit for detection of osteogenesis imperfecta includes a reagent for detection of the 1822bpth locus of a COL1A1 geneCDS or a reagent for detection of the 608th amino acid locus of a COL1A1 protein. The pathogenic mutation (c.1822G>A on the COL1A1 gene) of the osteogenesis imperfecta disease is obtained, and the osteogenesis imperfecta disease can be diagnosed by detecting the mutation.

An anti-HBs monoclonal antibody is described herein. This antibody can bind to the following: a wild type HBsAg; at least one mutant HBsAg selected from the group consisting of a first mutant HBsAg and a second mutant HBsAg; and at least one mutant HBsAg selected from the group consisting of a third mutant HBsAg and a fourth mutant HBsAg. The first mutant HBsAg has a mutation at position 120. The second mutant HBsAg has a mutation at position 141. The third mutant HBsAg has a substitution to a lysine at position 118. The fourth mutant HBsAg has only one mutation at position 144 and an amino acid at the position 144 is substituted by a glutamic acid.

The present invention refers to non-human transgenic mammals, preferably rodents, or mice, which comprise a mutation in the gene encoding for the cardiac ryanodine receptor (RyR2).

Transgenic animals carrying the amino acid change R4496C in the RyR2 protein show a phenotype similar to that of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (OMIM: 604772). Further provided are methods for using these animals as in vivo model of Catecholaminergic Polymorphic Ventricular Tachycardia and RyR2 dependent arrhythmias, in drug screening and for understanding the molecular basis of RyR2 dependent arrhythmias.

The invention discloses an obese receptor (OB) gene and application thereof as a goose fat character genetic marker. Genetic markers in the OB gene relevant to goose abdominal fat weight and abdominal fat rate are determined, and the polymorphism in the OB gene in a nucleic acid sample obtained from a goose is determined and causes that the coded amino acid changes and is relevant to the abdominal fat weight and the abdominal fat rate. According to the single nucleotide polymorphism of the OB gene, animals containing the OB genes in a genome DNA are subjected to fatty breeding, and protogene types reducing the abdominal fat weight and abdominal fat rate of the goose are screened, thus the OB gene has important application value and economic benefit.

The invention relates to the technical field of protein modification site identification, in particular to a protein kinase specificity prediction method and device based on a nearest neighbor algorithm. According to the prediction method, amino acid information on the upstream and the downstream of a phosphorylation site is fully utilized, and the accuracy of prediction is increased. According to the protein kinase specificity prediction method, an amino acid permutation matrix is used for scoring the similarity of a phosphorylation site peptide fragment to be detected and a known phosphorylation site peptide fragment, the phosphorylation site peptide fragment to be detected is marked to be the highest scored known phosphorylation site peptide fragment, and the sensitivity and the specificity of prediction are improved.